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ABSTRACT 
 
Background: Basal Cell Carcinoma (BCC) is a type of skin cancer, and a growing number of cases are diagnosed each 
year. There are many treatment options available, however finding the best treatment that has the lowest recurrence rate 
and morbidity is a challenge. The treatment options vary from topical or systemic medications to special procedures to 
surgical interventions. Treatment’s effectiveness largely differs on the BCC sub-type and its individual features. Method: 
Data was collected from the charts of patients that were diagnosed with BCC. The selected patients were treated by either 
Mosh surgery or Imiquimod. Results: Majority of patients who were diagnosed with BCC had light skin color. Some 
patients had recurrence of the disease after Imiquimod treatment. However, no patient had any recurrence with Mohs 
surgery. Conclusion: This study shows that Mohs surgery provides superior treatment outcome than many other options. 
However, cost of the procedure can be an issue to patients with lower income or lack of proper health insurance. 
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INTRODUCTION 
 
Basal Cell Carcinoma (BCC) is a common forms of 
human skin cancer, and have become a great public 
health concern. Due to a rising rate of diagnosis and 
high rate of morbidity from the disease, finding the 
best treatment becomes an important priority.[1] Each 
year, more than 5 million cases are diagnosed with 
nonmelanoma skin cancer (NMSC). Among those 
patients, 80% are basal cell carcinomas. Although, 
mortality rate for these types of cancers are very 
low; however, the number of cases are increasing, 
which may be due to early diagnosis, higher sun 
exposure and elderly patients are living longer.[2] 
Basal cell carcinoma has high morbidity and 
increased cost to health services, in spite of the low 
death rate.[3] Nonmelanoma skin cancer is mainly 
divided into basal cell carcinoma and squamous cell 
carcinoma with an estimated cost $4.8 billion per 
year.[4] The treatment options are determined largely 
by how easily the tumors may be excised as well as 
the lesion’s depth of penetration into the skin. The 
following treatment options are available for 
treatment of basal cell carcinoma.    
Cryotherapy is a treatment that involves a fine mist  
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of liquid nitrogen that freezes living tissue. This 
effectively kills abnormal cells, in addition to normal 
cells. The death of all the tissue in a small area will 
make it possible for healthy cells to replenish the 
dead tissue. Depending on how deep the lesion 
protrudes, longer or shorter freeze thaw cycles may 
be used to increase the chance of complete removal. 
This is usually a quick, but rather painful treatment 
that has been used as an initial treatment for many 
cases. Cryosurgery is an effective treatment modality 
for eyelid basal cell carcinomas, resulting in few 
recurrences and good cosmetic and functional 
outcomes at a low cost.[5] Compared with surgical 
techniques, cryotherapy has a cure rate of 85 – 90%. 
This is the main reason that it is less commonly 
used.[6] 
Imiquimod (IMQ) 5% cream is an 
immunomodulatory and antitumorigenic agent, 
which is used as a topical treatment regimen, who 
had periocular basal cell carcinoma (BCC).[7] This is 
typically not painful, but requires a longer period of 
time for treatment to be successful. Duration of 
treatment is usually about 6 weeks, and can be very 
costly if the lesion is very large.[8] 
Standard surgical excision is primarily done for most 
cases.[9] The tumor is generally removed with a 4mm 
vertical margin and the sample is sent to a 
pathologist for examination via bread-loaf 
microscopy. There is between a 1.5% and 28.5% 
risk of incomplete removal which would be 
recognized in the pathology report of the specimen 
after surgery.[10] Errors may also take place on the 
sectioning technique used by the pathologist. Bread-
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loaf microscopy (vertical sections) does not examine 
the margins to the extent it may need, and thus may 
result in a possible overlook of a tumor nest existing 
beyond the border of excision. This overlook would 
then result in another round of excisions.[11] This 
would result in additional surgery with extra cost, or 
the cancer could persist and silently lurk throughout 
the patient’s body.[12] 
Mohs surgery is a more careful and precise 
procedure, which allows for less significant defects 
after treatment.[13] It is cost-effective, especially 
when dealing with poorly demarcated, high-risk, 
facial tumors, where it should be considered as the 
first choice of treatment.[14] Five-year recurrence 
rates using Kaplan-Meier survival analysis is very 
low for previously untreated BCC.[15]  
Radiotherapy can be used for facial lesions; 
however, treatment failure is higher in aggressive 
tumors and healing is delayed for weeks or even 
months.[16]  
Photodynamic therapy is useful for superficial 
lesions only because it cannot properly penetrate to 
deeper parts of skin.[16] The cure rate for PDT is 
between 70 – 90%.[6] 
 
MATERIALS AND METHODS 
 
A total of 60 patients’ charts from a local 
dermatology clinic were reviewed for this study. 
These patients received either Imiquimod or Mohs 
surgery. Patients’ data including skin color, gender, 
and age as well as cost, and treatment outcomes 
were recorded.  In Mohs surgery, once the skin was 
removed, the entire sample was instantly prepped for 
histological evaluation. The pathologist then 
examined the sample to decide if the borders were 
clear of malignancy. If not, the surgical mark was 
expanded in the direction of its microscopic, 
observable location.  Patients were followed up in 
one year after Mohs surgery. 
In patients who received Imiquimod cream, 
successful treatment was determined by a physician, 
after a complete initial cycle of application 4-8 
weeks, depending on the size and sub-type of BCC. 
Imiquimod complete success was considered 1 year 
after last application. 
 
RESULTS  
 
Out of 60 patients diagnosed with BCC, 45 patients 
received Mohs surgery and 15 patients received 
Imiquimod. Thirty-eight patients were men and 22 
were women. Based on skin color type using the 
Fitzpatrick’s scale, 17% were very pale white, 28% 
were while/fair, 37% were white/olive, 13% were 
medium/dark brown, and only 5% were very dark 
brown/black. Of those that were diagnosed with 
BCC, 7 patients were between the ages of 21 and 45 
years, 17 patients were between 46 and 65 years and 
the remaining 36 patients were over 65 years old. 
None of the patients were under the age of 20 years.  
The recurrence rate varied based on treatment 
modality. There was no recurrence in patients who 
received Mohs Surgery. Three patients who received 
Imiquimod treatment had recurrent disease (20%). 
Analysis of cost of both treatments showed that 
Mohs surgery had the higher cost ($1,050) compared 
with Imiquimod ($800). These fees were out of 
pocked cost for patients and did not account for 
insurance coverage. 
 
DISCUSSION 
 
Although, the most likely type of skin tone that was 
diagnosed with BCC was white/olive presumably 
due to decreased level of protection from melanin 
pigment; however, the cancer also developed even in 
patients with very dark/black skin. Additionally, age 
was also a factor that seemed to play a part in BCC 
diagnosis. According to data, prevalence was higher 
in older population. This could be due to a 
development of accumulated mutations over the 
course of a longer time of life. Moreover, the skin 
may not visibly show signs of damage until many 
years later after exposure, especially if it is long-term 
or consistent exposure. Furthermore, men were 
almost twice as likely to be diagnosed with BCC 
than females; however, it should also be noted that 
this may not be necessarily due to genetic pre-
disposition of the sexes. There are a variety of 
factors to consider, such as, the possibility that men 
may be less likely to notice an odd lump/lesion than 
women possibly due to facial hair, or higher 
exposure to UV radiation due to participation in 
more outdoor activities.  
The success of treatments was based of BCC 
recurrence rates for each type of treatment. Only 
three of the fifteen patients who were treated with 
Imiquimod returned for recurrence; however, 
Imiquimod is usually given to patients with smaller, 
less severe lesions. The sample size was also small 
in this case. Surgical excisions were more often 
prescribed for the best outcomes as Imiquimod is a 
relatively new treatment option. Thus, patients 
receiving Imiquimod treatment, most likely had a 
lesion that was not likely to pose as much of a risk or 
the location made excisional surgery difficult to 
carry out.  
The most promising type of treatment was Mohs 
Surgery because none of the treated patients had 
recurrence of BCC. In standard surgical excision, 
initial treatment is considered successful if the BCC 
is determined to be completely removed via 
microscopy. However, in the Mohs surgery, specific 
training and personal judgment of the physician is 
needed to remove the entire malignancy but at the 
same time minimizing the amount of skin loss. It is 
the best type of treatment for BCC, if it is done by a 
careful, skilled professional on a proper candidate. 
 Saleem & Robinson; Mohs Surgery vs. Imiquimod in Basal Cell Carcinoma 
Annals of International Medical and Dental Research, Vol (4), Issue (2) Page 3 
 
S
ectio
n
:
 S
u
rgery 
 
When considering a proper candidate for treatment 
options, it is determined at the discretion of the 
physician. The physician would consider the size, 
shape and color of the lesion as well as how deep it 
may protrude. In addition, other factors to consider 
for choosing the correct treatment option include 
how long the lesion has been there as well as 
patient’s age, medical history, and lifestyle.  
The average billing for Mohs Surgery is higher than 
Imiquimod. However, the cost of treatment varies 
widely for different regions and countries. 
 
CONCLUSION 
 
With so many cases of NMSC diagnosed each year, 
research for diagnosis and treatments are essentially 
vital. Although NMSC generally sees very high cure 
rates and good cosmetic outcomes, it remains a 
public health crisis due to the large number of people 
effected.  The treatment plans for a wide variety of 
skin irregularities are usually similar, differing 
mainly on how deep its protrusion is. Another 
important factor for determining a treatment plan 
includes the risk of incomplete removal. If a 
pathology report even slightly hints that a lesion may 
radiate outward in small abundance, its removal 
must be done extremely carefully. Finally, the 
physician must consider the outcome based on 
appearance and/or lifestyle of the patient to 
minimize the amounts and severity of defects after 
treatment. Mohs surgery is the most successful 
treatment option for BCC, even though it is more 
expensive than alternative treatments. Future 
direction is required to collect and analyze larger 
sample data for recurrence rates of BCC since it is 
largely categorized together, along with SCC within 
the broader category of NMSC. 
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